Compare MIAX & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIAX | TMDX |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | 728 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.2B |
| IPO Year | 2025 | 2019 |
| Metric | MIAX | TMDX |
|---|---|---|
| Price | $43.99 | $122.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $47.20 | ★ $144.25 |
| AVG Volume (30 Days) | ★ 1.2M | 664.3K |
| Earning Date | 02-22-2026 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 170.70 |
| EPS | N/A | ★ 2.54 |
| Revenue | ★ $1,318,535,000.00 | $566,354,000.00 |
| Revenue This Year | N/A | $38.81 |
| Revenue Next Year | $19.04 | $20.49 |
| P/E Ratio | ★ N/A | $47.97 |
| Revenue Growth | 22.86 | ★ 41.20 |
| 52 Week Low | $28.63 | $55.00 |
| 52 Week High | $51.38 | $156.00 |
| Indicator | MIAX | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 42.70 |
| Support Level | N/A | $121.00 |
| Resistance Level | N/A | $133.29 |
| Average True Range (ATR) | 0.00 | 4.77 |
| MACD | 0.00 | -0.83 |
| Stochastic Oscillator | 0.00 | 22.79 |
Miami International Holdings Inc is a technology-driven leader in building and operating regulated financial marketplaces across multiple asset classes and geographies. Its MIAX Exchange marketplaces are enabled by its in-house built, proprietary technology. It maintains a broad portfolio of U.S. exchange and clearing licenses, in both securities and futures. The company operates markets across a diverse number of asset classes including options and cash equities as well as futures and options on futures.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.